ISRCTN60323736已完成1 期
Riociguat in patients with respiratory disease and hypoxia – a proof-of-concept study
ewcastle Hospitals Foundation NHS Trust0 个研究点目标入组 10 人开始时间: 2015年3月11日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 10
研究概览
简要总结
2017 conference abstract in https://erj.ersjournals.com/content/48/suppl_60/pa2436.abstract (added 07/05/2021) (published 21/05/2017)
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Age 40 to 80 years, Male and Female
- •2. Primary diagnosis of either chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF) with recent stability
- •3.Capacity and willingness to provide fully informed consent for participation in the study
排除标准
- •1. On prescribed oxygen therapy, nitrates (tablets or sublingual), dipyridamole, theophylline, warfarin, clopidogrel, rivaroxaban and dabigatran
- •2. Other concomitant respiratory diagnoses including asthma, interstitial lung disease (not idiopathic), pulmonary hypertension (of any other aetiology), lung cancer, recent respiratory infection, recent acute pulmonary embolism, recent pneumothora
- •3. Unable to give written, informed consent
- •Contraindication to spirometry not included elsewhere: recent eye surgery, glaucoma
- •4. Uncontrolled arterial hypertension (systolic BP > 180mmHg and/or diastolic BP > 110mmHg
- •5. Systolic BP < 95mmHg
- •6. Resting awake heart rate < 50 beats per minute or > 105bpm
- •7. History of uncontrolled atrial fibrillation within 3 months of screening
- •8. Left heart failure with an ejection fraction less than 40%
- •9. Hypertrophic Obstructive Cardiomyopathy (HOCM)
- •10. Proven or suspected active or recent* coronary artery disease
- •11. Other active atherosclerotic disease: active peripheral arterial disease, stroke within 3 months of screening
- •12. Significant valvular heart disease
- •13. History of active or serious haemoptysis/pulmonary haemorrhage
- •14. Hepatic dysfunction
- •15. Bilirubin > 2 times ULN at screening and/or
- •16. ALT or AST > 3 times ULN at screening and/or
- •17. Albumin < 32g/L/hepatic encephalopathy > grade 1 at screening
- •18. Renal insufficiency: GFR < 30ml/min
- •19. Pregnant or lactating women
研究者
相似试验
进行中(未招募)
1 期
Riociguat in patients with respiratory disease hypoxia - a proof-of-concept studyPulmonary hypertension WHO Group III (Pulmonary hypertension owing to lung disease and/or hypoxia): Chronic obstructive pulmonary disease(COPD)Pulmonary Fibrosis (PF).MedDRA version: 18.1Level: PTClassification code 10037400Term: Pulmonary hypertensionSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2014-001008-23-GBThe Newcastle Upon Tyne Hospital NHS Foundation Trust, Freeman Hospital12
已完成
3 期
Riociguat Clinical Effects Studied in Patients With Insufficient Treatment Response to Phosphodiesterase-5 InhibitorHypertension, PulmonaryNCT02007629Bayer61
已完成
1 期
Effect of Riociguat on Bone MetabolismPharmacology, ClinicalNCT00855660Bayer17
已完成
不适用
Prospective, Non-interventional, Multi-center Post-authorization Safety Study of Riociguat for Chronic Thromboembolic Pulmonary Hypertension (CTEPH )Hypertension, PulmonaryNCT02117791Bayer1,298
已完成
Unknown
Clinical effect of multidisciplinary respiratory rehabilitation including nutrition support with BCAA and herbal medicineRespiratory disease.lung cancer patients with poor lung functionJPRN-jRCT1090220049Hiroaki Harada100
